Table 4.
Univariate analysis of recurrence factors for DFS of endometrial carcinoma in training group
| Predictive factors | Recurrence | ||
|---|---|---|---|
| HR | 95%CI | p-value | |
| Age at diagnosis | 1.61 | 0.58–4.45 | 0.537 |
| FIGO stage (I–II vs. III–IV) | 5.15 | 1.92–13.86 | < 0.001 |
| Tumor size (< 3.5 cm vs. ≥3.5 cm) | 1.79 | 0.62–5.14 | 0.274 |
| Pathological types (endometrioid vs. non-endometrioid) | 3.49 | 1.26–9.65 | 0.01 |
| Myometrial invasion (< 50% vs. ≥50%) | 2.97 | 1.07–8.23 | 0.027 |
| LVSI (absent vs. present) | 0.53 | 0.12–2.33 | 0.388 |
| LNM (absent vs. present) | 1.49 | 0.42–5.23 | 0.529 |
| Ki-67 (< 50% vs. ≥50%) | 0.91 | 0.34–2.46 | 0.857 |
| ADCmean (> 0. 795 vs. ≤0.795) | 4.98 | 1.81–13.74 | 0.001 |
| ADCmin (> 0.743 vs. ≤0.743) | 4.48 | 1.02–19.79 | 0.029 |
| ADCmax (> 1.154 vs. ≤1.154) | 2.16 | 0.75–6.23 | 0.142 |
| Radscore (<−1.227 vs. ≥ − 1.227) | 7.88 | 2.73–22.78 | < 0.001 |
LVSI lymphovascular space invasion, LNM lymph node metastasis, ADC apparent diffusion coefficient, HR hazard ratio, CI confidence interval